Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Soligenix Mid-Year Report Strong for Biodefense Efforts

by Global Biodefense Staff
August 12, 2015
Biodefense and Health Security Industry News

Soligenix, Inc., a late-stage biopharmaceutical company developing products in the areas of biodefense, inflammation, and oncology, today announced highlights and financial results for the first half of 2015.

During this timeframe, the company initiated a development agreement with Emergent BioSolutions Inc. to implement a commercially viable, scalable production process for the RiVax, a vaccine candidate being developed for protection against ricin exposure.

Under the agreement, Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.

Also on the biodefense front, Soligenix this year expanded their ThermoVax technology platform via a collaboration with the University of Hawaiʻi at Manoa and Hawaii Biotech, Inc. to develop a heat stable Ebola vaccine.

In addition, Soligenix entered a collaboration with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to support recruitment into the SGX301 pivotal Phase 3 cutaneous T-cell lymphoma (CTCL) clinical study set to begin in the second half of 2015.

“Following the end of the second quarter, we increased our access to capital by entering into a $10 million equity purchase agreement with accredited investors,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “This funding, to be used at our sole discretion, has the potential to fund ongoing development initiatives for our late-stage product candidates, including the Phase 3 CTCL clinical study. Our cash position for the second quarter ended June 30, 2015 was $4.0 million versus $5.0 million at March 31, 2015.”

In June 2015, Soligenix also announced the publication of data by the University of Colorado demonstrating a heat stable vaccine formulation of a Human Papillomavirus (HPV) vaccine. Soligenix has not licensed or acquired any rights to this vaccine and related patent applications, but the study demonstrated the successful conversion of a commercial virus-like particle based vaccine requiring cold-chain storage to a subunit, alum adjuvanted, vaccine which is stable at ambient temperatures.

Source: Soligenix press release, adapted. Rivax and ThermoVax are trademarked, protected terms by Soligenix, Inc.

Tags: RicinStrategic National StockpileThermostabilityVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy